Component

Alpha-synuclein fibrils

Study-scoped entity; inspect species, exposure, model and limitations on each claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. EGCG bound mature fibrils and remodeled them into smaller amorphous aggregates without measured release of monomers or small diffusible oligomers.

    Epigallocatechin-3-gallate (EGCG) → Alpha-synuclein fibrils source_derived_draftungraded
    Experimental context and source evidence
    experimental_model
    Mature amyloid-beta and alpha-synuclein fibril preparations.
    limitations
    This does not show removal of deposits from a human brain.
    nutrient_topic
    EGCG collection; comparator and shared-pathway records retain their actual intervention. · Epigallocatechin-3-gallate (EGCG)
    plain_language
    EGCG changed pre-existing aggregates in a laboratory experiment.
    primary_references
    EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20385841/ · DOI 10.1073/pnas.0910723107

    EGCG: receptor signaling, metabolism, nutrient interactions and discovery questions (2026-09-18) · lines 364–370

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Mature amyloid-beta and alpha-synuclein fibril preparations. · source_derived_draft · unverified_draft

    ## egcg-as-remodel EGCG changed pre-existing aggregates in a laboratory experiment. EGCG bound mature fibrils and remodeled them into smaller amorphous aggregates without measured release of monomers or small diffusible oligomers. Model: Mature amyloid-beta and alpha-synuclein fibril preparations. Limitations: This does not show removal of deposits from a human brain. Evidence access: primary abstract. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20385841/ · DOI 10.1073/pnas.0910723107
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. The reagent reduced alpha-synuclein aggregation signals in co-cultures; proteinase-K resistance was not significantly reduced in transfected-only cells.

    Defined fungal fulvic acid / CAS 479-66-3 → Alpha-synuclein aggregation in human HEK293 co-cultures source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    2020 study; Cayman CAS 479-66-3 at 37 micromolar; HEK293 constructs or purified K18 tau as specified.
    limitations
    The methods identify a defined fungal compound, not an interchangeable environmental mixture. Supplier identity: https://www.caymanchem.com/product/19063/fulvic-acid . No clinical efficacy or CNS exposure was measured. Disassembly of all pre-existing alpha-synuclein aggregates was not established.
    nutrient_topic
    Fulvic acid collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Fulvic acid (heterogeneous humic fraction)
    plain_language
    The effect depended on how aggregates were produced and measured.
    primary_references
    Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization. · 2020 · https://pubmed.ncbi.nlm.nih.gov/32732936/ · DOI 10.1038/s41598-020-69744-y

    Fulvic acid: mixture identity, mineral chemistry, signaling and cross-nutrient mechanisms (2026-09-19) · lines 180–186

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · 2020 study; Cayman CAS 479-66-3 at 37 micromolar; HEK293 constructs or purified K18 tau as specified. · source_derived_draft · unverified_draft

    ## fulvic-acid-defined-synuclein The effect depended on how aggregates were produced and measured. The reagent reduced alpha-synuclein aggregation signals in co-cultures; proteinase-K resistance was not significantly reduced in transfected-only cells. Model: 2020 study; Cayman CAS 479-66-3 at 37 micromolar; HEK293 constructs or purified K18 tau as specified. Limitations: The methods identify a defined fungal compound, not an interchangeable environmental mixture. Supplier identity: https://www.caymanchem.com/product/19063/fulvic-acid . No clinical efficacy or CNS exposure was measured. Disassembly of all pre-existing alpha-synuclein aggregates was not established. Evidence access: Primary full text Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization. · 2020 · https://pubmed.ncbi.nlm.nih.gov/32732936/ · DOI 10.1038/s41598-020-69744-y
    Complete structured claim and evidence

  2. EGCG bound unfolded amyloid-beta and alpha-synuclein and redirected assembly toward unstructured, relatively nontoxic oligomers in the experimental system.

    Epigallocatechin-3-gallate (EGCG) → Amyloid fibril formation in specified assays source_derived_draftungraded
    Experimental context and source evidence
    experimental_model
    Biophysical and cell-based aggregation experiments.
    limitations
    Not evidence of preventing or treating human neurodegenerative disease.
    nutrient_topic
    EGCG collection; comparator and shared-pathway records retain their actual intervention. · Epigallocatechin-3-gallate (EGCG)
    plain_language
    EGCG changed how these proteins assembled.
    primary_references
    EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. · 2008 · https://pubmed.ncbi.nlm.nih.gov/18511942/ · DOI 10.1038/nsmb.1437

    EGCG: receptor signaling, metabolism, nutrient interactions and discovery questions (2026-09-18) · lines 348–354

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Biophysical and cell-based aggregation experiments. · source_derived_draft · unverified_draft

    ## egcg-amyloid-initiation EGCG changed how these proteins assembled. EGCG bound unfolded amyloid-beta and alpha-synuclein and redirected assembly toward unstructured, relatively nontoxic oligomers in the experimental system. Model: Biophysical and cell-based aggregation experiments. Limitations: Not evidence of preventing or treating human neurodegenerative disease. Evidence access: primary abstract. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. · 2008 · https://pubmed.ncbi.nlm.nih.gov/18511942/ · DOI 10.1038/nsmb.1437
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards